Alyra Therapeutics
Next-generation precision oncology
Alyra Therapeutics
Next-generation precision oncology
Who We Are
Where We Are
Who We Are
Headquartered in San Diego, CA with collaborators in Irvine, CA, Austin, TX and Genoa, Italy, we are a team of academic scientists and veteran pharmaceutical industry executives focused on developing novel first-in-class protein-protein interaction inhibitors for the treatment of cancer and rare diseases.
What We Do
Where We Are
Who We Are
Using an innovative drug discovery platform that integrates computational chemistry and both intracellular and biophysical assay technologies we have identified multiple inhibitors of the CDC42 and related families of protein switches that regulate growth and metastasis of cancer cells.
Where We Are
Where We Are
Where We Are
We are focused on our clinical lead compound, ALY101. A highly selective inhibitor of tumor growth and angiogenesis, ALY101 has activity against multiple tumor types in both in vitro and in vivo settings and has demonstrated the potential to impact the treatment of additional cancers as well as multiple rare diseases.